Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Abstract Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogen...

Full description

Saved in:
Bibliographic Details
Main Authors: Han-Chung Lee, Hamizun Hamzah, Melody Pui-Yee Leong, Hadri Md Yusof, Omar Habib, Shahidee Zainal Abidin, Eryse Amira Seth, Siong-Meng Lim, Sharmili Vidyadaran, Mohamad Aris Mohd Moklas, Maizaton Atmadini Abdullah, Norshariza Nordin, Zurina Hassan, Pike-See Cheah, King-Hwa Ling
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items